COSMOS HEALTH INC.

NASDAQ: COSM (Cosmos Health Inc.)

最近更新时间: 13 May, 4:52PM

0.349

0.00 (0.66%)

前收盘价格 0.347
收盘价格 0.350
成交量 254,739
平均成交量 (3个月) 451,846
市值 8,122,252
价格/销量 (P/S) 0.180
股市价格/股市净资产 (P/B) 0.520
52周波幅
0.311 (-10%) — 1.58 (352%)
利润日期 14 Nov 2024
营业毛利率 -28.26%
营业利益率 (TTM) -6.08%
稀释每股收益 (EPS TTM) -1.09
季度收入增长率 (YOY) -6.00%
总债务/股东权益 (D/E MRQ) 49.51%
流动比率 (MRQ) 1.05
营业现金流 (OCF TTM) -4.49 M
杠杆自由现金流 (LFCF TTM) -1.94 M
资产报酬率 (ROA TTM) -14.90%
股东权益报酬率 (ROE TTM) -50.03%

市场趋势

短期 中期
行业 Medical Distribution (US) 混合的 看跌
Medical Distribution (全球的) 混合的 看跌
股票 Cosmos Health Inc. - -

AIStockmoo 评分

0.5
分析师共识 0.0
内部交易活动 NA
价格波动 0.5
技术平均移动指标 2.5
技术振荡指标 -1.0
平均 0.50

相关股票

股票 市值 DY P/E(TTM) P/B
COSM 8 M - - 0.520
PDCO 3 B 1.67% 20.38 2.80
EDAP 59 M - - 1.54
HSIC 9 B - 23.22 2.80
ZYXI 76 M - 28.00 3.92
AHG 563 M - - 3.42

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

部门 Healthcare
行业 Medical Distribution
投资方式 Small Value
内部持股比例 31.08%
机构持股比例 9.46%

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
24 Jun 2025 公告 Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
24 Jun 2025 公告 Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech
15 May 2025 公告 Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
15 May 2025 公告 Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
07 May 2025 公告 Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
07 May 2025 公告 Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
06 May 2025 公告 Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
06 May 2025 公告 Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
30 Apr 2025 公告 Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
30 Apr 2025 公告 Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
16 Apr 2025 公告 Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
16 Apr 2025 公告 Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票